These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 12789620

  • 1. Ruboxistaurin (Eli Lilly).
    Wheeler GD.
    IDrugs; 2003 Feb; 6(2):159-63. PubMed ID: 12789620
    [Abstract] [Full Text] [Related]

  • 2. Ruboxistaurin: LY 333531.
    Drugs R D; 2007 Feb; 8(3):193-9. PubMed ID: 17472415
    [Abstract] [Full Text] [Related]

  • 3. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ.
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [Abstract] [Full Text] [Related]

  • 4. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 5. Fidarestat. Sanwa Kagaku/NC Curex/Sankyo.
    Giannoukakis N.
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1233-9. PubMed ID: 14649216
    [Abstract] [Full Text] [Related]

  • 6. Molecule of the month. Ruboxistaurin mesilate hydrate.
    Drug News Perspect; 2003 Dec; 16(10):691. PubMed ID: 14747848
    [No Abstract] [Full Text] [Related]

  • 7. Ruboxistaurin.
    Taulien CA, Joy SV.
    Drugs Today (Barc); 2006 Sep; 42(9):577-85. PubMed ID: 17028667
    [Abstract] [Full Text] [Related]

  • 8. Technology evaluation: pegaptanib, Eyetech/Pfizer.
    Vinores SA.
    Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
    [Abstract] [Full Text] [Related]

  • 9. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ, Wolka AM, Vinik AI.
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [Abstract] [Full Text] [Related]

  • 10. Ruboxistaurin for diabetic retinopathy.
    Gardner TW, Antonetti DA.
    Ophthalmology; 2006 Dec; 113(12):2135-6. PubMed ID: 17157131
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
    Danis RP, Sheetz MJ.
    Expert Opin Pharmacother; 2009 Dec; 10(17):2913-25. PubMed ID: 19929710
    [Abstract] [Full Text] [Related]

  • 14. [Protein kinase C beta-Inhibitor ruboxistaurin].
    Musch A.
    Med Monatsschr Pharm; 2005 Aug; 28(8):292-3. PubMed ID: 16128544
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PKC inhibition and diabetic microvascular complications.
    Clarke M, Dodson PM.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [Abstract] [Full Text] [Related]

  • 17. Protein kinase C-beta inhibition for diabetic kidney disease.
    Tuttle KR.
    Diabetes Res Clin Pract; 2008 Nov 13; 82 Suppl 1():S70-4. PubMed ID: 18977550
    [Abstract] [Full Text] [Related]

  • 18. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
    Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK.
    J Diabetes Complications; 2008 Nov 13; 22(2):88-95. PubMed ID: 18280438
    [Abstract] [Full Text] [Related]

  • 19. Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
    Giannoukakis N.
    Curr Opin Investig Drugs; 2006 Oct 13; 7(10):916-23. PubMed ID: 17086937
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological treatment of diabetic retinopathy.
    Lang GE.
    Ophthalmologica; 2007 Oct 13; 221(2):112-7. PubMed ID: 17380065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.